Acrivon Therapeutics has initiated a Phase 1 clinical trial for ACR-2316, a novel cancer treatment targeting WEE1/PKMYT1 using their proprietary AP3 platform, with the first patient already dosed. This drug, designed to cause complete tumor regression, has been rapidly advanced to trials, demonstrating the company’s efficient drug discovery process. The trial aims to evaluate the safety, tolerability, and optimal dosage of ACR-2316, with initial results expected in the second half of 2025. Acrivon is also progressing other preclinical programs, leveraging their AP3 platform for precision medicine in oncology.
https://finance.yahoo.com/news/acrivon-therapeutics-launches-phase-1-122846869.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.